Artiva Biotherapeutics, Inc. (0001817241) Files S-8 Form with SEC
Artiva Biotherapeutics, Inc. recently submitted a Form S-8 filing with the Securities and Exchange Commission (SEC), indicating its intention to issue shares of common stock to employees as part of its equity incentive plan. This filing is significant as it demonstrates the company’s commitment to incentivizing and retaining top talent through equity-based compensation, which can align the interests of employees with shareholders and drive long-term growth and success for the company.
Artiva Biotherapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies for the treatment of cancer. With a mission to harness the power of the immune system to target and destroy cancer cells, the company is at the forefront of cutting-edge research and development in the field of immuno-oncology. For more information about Artiva Biotherapeutics, Inc., please visit their website at https://www.artivabio.com.
Form S-8 is a registration statement filed by companies with the SEC to register securities that will be offered to employees under employee benefit plans, such as stock option plans or employee stock purchase plans. By filing a Form S-8, companies like Artiva Biotherapeutics, Inc. can provide transparency and regulatory compliance when issuing shares of common stock to employees as part of their compensation packages.
Read More:
Artiva Biotherapeutics, Inc. (0001817241) Files S-8 Form with SEC
